drugset

drugset / Trial / NCT04822805

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

NCT04822805 ↗

Phase 2 Unknown 27 enrolled First People's Hospital of Hangzhou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of anlotinib in treatment of recurrent high-grade glioma.

Timeline

Start: 2020-04-13
Primary completion: 2022-10-30
Completion: 2023-03-30

Publications

Zhao S, Zhang M, Zhang Q, Wu J, Dai H. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial. BMC Cancer. 2024 Jan 2;24(1):6. doi: 10.1186/s12885-023-11776-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	8 mg	Oral
Subject	Catequentinib	Small molecule	10 mg	Oral
Subject	Catequentinib	Small molecule	12 mg	Oral

Indications